UBS cuts Demant to 'neutral' on limited upside to earnings forecasts

Demant A/S

22/07/2026 11:32

** UBS downgrades Danish hearing aids maker Demant DEMANT.CO to "neutral" from "buy", citing limited potential for earnings forecasts to rise beyond current market expectations
** With several competitors, including Sonova SOON.S, poised for new product launches in H2, it will be harder for Demant to secure additional market share gains, UBS says
    ** The broker notes that while the new product Zeal offers a clear edge, its advantages are less obvious in the larger receiver-in-canal hearing aid segment
** It adds it will "pause for breath" and rate the stock "neutral", as Demant shares have significantly outperformed the sector this year on a strong product launch and market recovery
** Despite the downgrade, the broker raises price target by 4% to DKK 284, reflecting potential for higher market share gains and incremental margins for Zeal
** 14 out of 22 analysts rate the stock "strong buy"/"buy", seven "hold, one "sell" - LSEG data


($1 = 6.5516 Danish crowns)

 (Reporting by Vera Dvorakova)
 ((vera.dvorakova@thomsonreuters.com))